Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | TP53 | P04637 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15179454 | 0.92 | ALOX5 (0.54) | ALOX5EPHX2GAAMAPTTP53 | |
| SCHEMBL10120099 | 0.91 | ALOX5 (0.43) | ALOX5EPHX2GAAMAPTTP53 | |
| SCHEMBL15179316 | 0.91 | ALOX5 (0.45) | ALOX5EPHX2GAAMAPTTP53 | |
| SCHEMBL15179366 | 0.89 | ALOX5 (0.42) | ALOX5EPHX2GAAMAPTTP53 | |
| SCHEMBL15179461 | 0.89 | SLC2A1 (0.44) | ALOX5EPHX2GAAMAPTTP53 | |
| SCHEMBL10120193 | 0.88 | GAA (0.51) | ALOX5EPHX2GAAMAPTTP53 | |
| SCHEMBL10120187 | 0.87 | ALOX5 (0.51) | ALOX5GAAMAPTTP53SMN1; SMN2 | |
| SCHEMBL15179301 | 0.86 | GAA (0.43) | ALOX5GAAMAPTTP53SMN1; SMN2 | |
| SCHEMBL10120067 | 0.84 | MAPT (0.52) | ALOX5EPHX2GAAMAPTTP53 | |
| SCHEMBL10120061 | 0.83 | GAA (0.40) | ALOX5GAAMAPTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601194-B1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MERCK SHARP & DOHME (US) | 2016-05-25 | — | — | EP | disclosed |
| US-8871929-B2 | Fused-imidazoyl compounds useful as antimicrobial agents | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871929-B2 | Fused-imidazoyl compounds useful as antimicrobial agents | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130210816-A1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210816-A1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| WO-2012018662-A2 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | SCHERING CORPORATION (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210816-A1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MRPL21, ARG1, RPS4Y1 | ALOX5 4416/4885EPHX2 3506/4885GAA 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.